25-Jul-2020 | Market Research Store
Currently, the researchers are on the run to find all the means to treat COVID-19 through high-quality methods that provide reliable outcomes. At present, a team of British researchers have published a study claiming that a cheap steroid called dexamethasone is the only medication believed to help increase the chances of survival. There are two other studies that have proved the malaria drug hydroxychloroquine to be ineffective in people showing mild symptoms. Doctors and patients are in desperation to find therapies so as to get a clear picture of the virus’ behavior in the human body.
According to British Drs. Anthony Fauci and H. Clifford Lane of the National Institutes of Health there needs to be inconclusive studies conducted for better results on COVID-19. Some of the highlights of the recent studies conducted on treatment developments include:
DEXAMETHASONE
A team from the University of Oxford found the steroid to help lower inflammation that generally worsens in the later stages of COVID-19. The researchers concluded that the death rates reduced by 36% among people on breathing machines while by 18% in people needing supplemental oxygen. However, the toxic effects of the drug in the early stages or milder symptomatic patients are yet to be clarified.
HYDROXYCHLOROQUINE
The same team also tested hydroxychloroquine and affirmed the drug to be ineffectual in hospitalized patients with COVID-19. The study showed 25.7% on hydroxychloroquine to have died within 28 Days possibly due to the drug’s side effects. The drug was found to be futile even in the mild or early stages of the disease. Researchers from Spain and University of Minnesota found that hydroxychloroquine did not substantially ease symptom severity and instead added new side effects.
REMDESIVIR
Another helpful therapy is remdesivir that has shown positive effects on COVID-19 patients. The antiviral has shown to lower hospitalization by 4 Days on an average. The group of researchers from Memorial Sloan Kettering is now planning on a combinational therapy using dexamethasone and remdesivir.
In the process, Gilead Sciences that manufactures remdesivir as an IV is now testing its inhaled version to help lower the chances of hospitalization in less ill patients. For now, the supplies are limited are the U.S. government will have the doses allocated to hospitals from September.
Market Research Store has published the report on the global and China dexamethasone industry market. The report provides a professional and in-depth study on the current state of dexamethasone across the globe.